{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T21:01:11Z","timestamp":1784667671039,"version":"3.55.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ekir.2026.106367","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:33:38Z","timestamp":1771288418000},"page":"106367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systematic Review of Immunosuppression After Chimeric Antigen Receptor T-Cell Therapy for Posttransplant Lymphoproliferative Disorder"],"prefix":"10.1016","volume":"11","author":[{"given":"David","family":"Synnott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donal J.","family":"Sexton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.106367_bib1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(84)90994-2","article-title":"Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy","volume":"1","author":"Starzl","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106367_bib2","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJM199012203232510","article-title":"Cancers complicating organ transplantation","volume":"323","author":"Penn","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106367_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13669","article-title":"Post-transplant malignancy in solid organ transplant recipients in Ireland, The Irish Transplant Cancer Group","volume":"33","author":"O'Neill","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.ekir.2026.106367_bib4","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2015-05-615872","article-title":"How I treat posttransplant lymphoproliferative disorders","volume":"126","author":"Dierickx","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2026.106367_bib5","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/ndt\/gfq231","article-title":"Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease?","volume":"25","author":"Mucha","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"73","key":"10.1016\/j.ekir.2026.106367_bib6","first-page":"e1","article-title":"Efficacy and toxicity of CD19 chimeric antigen receptor T Cell therapy for lymphoma in solid organ transplant recipients: a systematic review and meta-analysis","volume":"30","author":"Yamshon","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.ekir.2026.106367_bib7","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106367_bib8","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106367_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106367_bib10","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106367_bib11","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-hodgkin lymphoma: an expert panel opinion from the american society for transplantation and cellular therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ekir.2026.106367_bib12","doi-asserted-by":"crossref","first-page":"796","DOI":"10.2215\/CJN.12871117","article-title":"Chimeric antigen receptor T cell therapy and the kidney: what the nephrologist needs to know","volume":"13","author":"Jhaveri","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106367_bib13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.blre.2015.10.003","article-title":"Chimeric antigen receptor T cell therapy: 25years in the making","volume":"30","author":"Gill","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.ekir.2026.106367_bib14","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ekir.2026.106367_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2026.106367_bib16","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1053\/j.ajkd.2021.07.012","article-title":"Kidney transplant T cell-mediated rejection occurring after anti-CD19 CAR T cell therapy for refractory aggressive Burkitt-like Lymphoma With 11q Aberration: a case report","volume":"79","author":"de Nattes","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106367_bib17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bjh.18763","article-title":"Post-transplant lymphoproliferative disorder: update on treatment and novel therapies","volume":"201","author":"Atallah-Yunes","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ekir.2026.106367_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13861","article-title":"Treatment of post-transplant lymphoproliferative disorder (PTLD) in a heart transplant recipient with chimeric antigen receptor T cell therapy","volume":"25","author":"Dang","year":"2021","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.ekir.2026.106367_bib19","article-title":"Safety and efficacy of anti-CD19-chimeric antigen receptor T cell combined with programmed cell death 1 inhibitor therapy in a patient with refractory post-transplant lymphoproliferative disease: case report and literature review","volume":"11","author":"Feng","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ekir.2026.106367_bib20","article-title":"CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review","volume":"69","author":"Hernani","year":"2021","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.ekir.2026.106367_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.14740\/jh1211","article-title":"Successful treatment of refractory post-transplant lymphoproliferative disorder with chimeric antigen receptor T cell therapy in a heart transplant recipient","volume":"13","author":"Hickmann","year":"2024","journal-title":"J Hematol"},{"key":"10.1016\/j.ekir.2026.106367_bib22","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.clml.2023.05.007","article-title":"CAR T cell therapy for post-transplant lymphoproliferative disorder after solid organ transplantation: a safe and feasible therapy for an orphan disease","volume":"23","author":"Ibrahim","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ekir.2026.106367_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2216116","article-title":"Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD)","volume":"19","author":"Kline","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ekir.2026.106367_bib24","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/ajt.16367","article-title":"CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder","volume":"21","author":"Krishnamoorthy","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2026.106367_bib25","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/s41409-020-01145-1","article-title":"Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series","volume":"56","author":"Luttwak","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ekir.2026.106367_bib26","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1182\/blood.2020008759","article-title":"Safety of CAR T cell therapy in kidney transplant recipients","volume":"137","author":"Mamlouk","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2026.106367_bib27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/bjh.18828","article-title":"Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed\/refractory solid organ transplant-related PTLD","volume":"202","author":"McKenna","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ekir.2026.106367_bib28","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.xkme.2021.03.011","article-title":"Acute kidney injury following chimeric antigen receptor T cell therapy for B-cell lymphoma in a kidney transplant recipient","volume":"3","author":"Melilli","year":"2021","journal-title":"Kidney Med"},{"key":"10.1016\/j.ekir.2026.106367_bib29","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jaccao.2022.09.002","article-title":"Successful CAR T cell therapy in a heart and kidney transplant recipient with refractory PTLD","volume":"4","author":"Oren","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.ekir.2026.106367_bib30","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41409-022-01907-z","article-title":"CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review","volume":"58","author":"Portuguese","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ekir.2026.106367_bib31","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000733","article-title":"CAR T cell infusion following checkpoint inhibition can induce remission in chemorefractory post-transplant lymphoproliferative disorder of the CNS","volume":"6","author":"R\u00f6sler","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.ekir.2026.106367_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhlto.2024.100101","article-title":"Chimeric antigen receptor T cell therapy for refractory post-transplant lymphoproliferative disorder after lung transplantation","volume":"5","author":"Veit","year":"2024","journal-title":"JHLT Open"},{"key":"10.1016\/j.ekir.2026.106367_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.70006","article-title":"CAR-T cell therapy for PTLD: analysis of car-t product, engraftment, and outcomes in patients receiving parallel immunosuppression","volume":"6","author":"Panopoulou","year":"2025","journal-title":"EJHaem"},{"key":"10.1016\/j.ekir.2026.106367_bib34","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s11912-023-01418-0","article-title":"Important considerations in the diagnosis and management of post-transplant lymphoproliferative disorder","volume":"25","author":"Lee","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ekir.2026.106367_bib35","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1093\/ndt\/gfv260","article-title":"Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients","volume":"30","author":"Taylor","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2026.106367_bib36","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106367_bib37","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T cell therapy in autoimmune disease - A case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106367_bib38","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.4049\/jimmunol.1002983","article-title":"B lymphocytes differentially influence acute and chronic allograft rejection in mice","volume":"186","author":"DiLillo","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.ekir.2026.106367_bib39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ekir.2026.106367_bib40","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T cell lymphoma after CAR T cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106367_bib41","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-Cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ekir.2026.106367_bib42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","article-title":"CAR-T cell therapy embarks on autoimmune disease","volume":"60","author":"Rampotas","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ekir.2026.106367_bib43","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41591-024-03478-6","article-title":"Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies","volume":"31","author":"Jadlowsky","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ekir.2026.106367_bib44","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2165\/00002018-199513030-00002","article-title":"Corticosteroids in kidney transplant recipients. Safety issues and timing of discontinuation","volume":"13","author":"Tarantino","year":"1995","journal-title":"Drug Saf"},{"key":"10.1016\/j.ekir.2026.106367_bib45","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ekir.2026.106367_bib46","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2026.106367_bib47","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical efficacy of anakinra to mitigate CAR T cell therapy-associated toxicity in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ekir.2026.106367_bib48","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor t cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ekir.2026.106367_bib49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","article-title":"Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy","volume":"16","author":"Mahadeo","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ekir.2026.106367_bib50","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.2165\/11319260-000000000-00000","article-title":"Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection","volume":"69","author":"Marc\u00e9n","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.ekir.2026.106367_bib51","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106367_bib52","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2165\/11635690-000000000-00000","article-title":"Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens","volume":"72","author":"Murukesan","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.ekir.2026.106367_bib53","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1600-6143.2004.00765.x","article-title":"Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients","volume":"5","author":"Opelz","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2026.106367_bib54","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/bjh.17421","article-title":"Front-line management of post-transplantation lymphoproliferative disorder in adult solid organ recipient patients - A British Society for Haematology Guideline","volume":"193","author":"Shah","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ekir.2026.106367_bib55","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1600-6143.2010.03387.x","article-title":"Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(\u2605)","volume":"11","author":"Reshef","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2026.106367_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2024.100837","article-title":"Post-transplant lymphoproliferative disorders following kidney transplantation: a literature review with updates on risk factors, prognostic indices, screening strategies, treatment and analysis of donor type","volume":"38","author":"Ergisi","year":"2024","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.ekir.2026.106367_bib57","first-page":"239","article-title":"Survival of post-transplant lymphoproliferative disorder after kidney transplantation in patients under rapamycin treatment","volume":"15","author":"Ashrafi","year":"2021","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"key":"10.1016\/j.ekir.2026.106367_bib58","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.080068597","article-title":"The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders","volume":"97","author":"Majewski","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ekir.2026.106367_bib59","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1097\/01.TP.0000063934.89714.19","article-title":"Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses","volume":"75","author":"Majewski","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2026.106367_bib60","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.1158\/1078-0432.CCR-21-0452","article-title":"Rapamycin pretreatment rescues the bone marrow AML cell elimination capacity of CAR-T cells","volume":"27","author":"Nian","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ekir.2026.106367_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.798352","article-title":"Case report: sirolimus alleviates persistent cytopenia after CD19 CAR-T cell therapy","volume":"11","author":"Xing","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.ekir.2026.106367_bib62","article-title":"Rapamycin enhances CAR-T control of HIV replication and reservoir elimination in vivo","volume":"137","author":"Mu","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ekir.2026.106367_bib63","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1432-2277.2011.01386.x","article-title":"Belatacept: from rational design to clinical application","volume":"25","author":"Wekerle","year":"2012","journal-title":"Transpl Int"},{"key":"10.1016\/j.ekir.2026.106367_bib64","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by the American society of transplant and cellular therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.ekir.2026.106367_bib65","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia after chimeric antigen receptor (CAR) T cell therapy: characteristics, management, and future directions","volume":"10","author":"Wat","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.ekir.2026.106367_bib66","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.1038\/s41467-023-44176-0","article-title":"Cyclosporine A-resistant CAR-T cells mediate antitumour immunity in the presence of allogeneic cells","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ekir.2026.106367_bib67","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1016\/j.ymthe.2024.06.022","article-title":"Immunosuppressant therapy averts rejection of allogeneic FKBP1A-disrupted CAR-T cells","volume":"32","author":"Maldini","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.ekir.2026.106367_bib68","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.ymthe.2024.11.035","article-title":"Managing allorejection in off-the-shelf CAR-engineered cell therapies","volume":"33","author":"Li","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.ekir.2026.106367_bib69","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.3390\/cancers16193339","article-title":"Advancement and challenges in monitoring of CAR-T cell therapy: a comprehensive review of parameters and markers in hematological malignancies","volume":"16","author":"Ploch","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ekir.2026.106367_bib70","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1078-0432.CCR-22-1654","article-title":"Monitoring of circulating tumor DNA predicts response to treatment and early progression in follicular lymphoma: results of a prospective pilot study","volume":"29","author":"Fern\u00e1ndez-Miranda","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ekir.2026.106367_bib71","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/ndt\/gfac044","article-title":"Adrenal insufficiency is common amongst kidney transplant recipients receiving maintenance prednisolone and can be predicted using morning cortisol","volume":"38","author":"Tomkins","year":"2023","journal-title":"Nephrol Dial Transplant"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926025982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926025982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T20:02:35Z","timestamp":1784664155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926025982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2468024926025982"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106367","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Review of Immunosuppression After Chimeric Antigen Receptor T-Cell Therapy for Posttransplant Lymphoproliferative Disorder","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106367","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106367"}}